Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Vaxcyte (PCVX) Receivables - Other (2020 - 2025)

Vaxcyte (PCVX) has 6 years of Receivables - Other data on record, last reported at $21.4 million in Q4 2025.

  • On a quarterly basis, Receivables - Other rose 5.4% to $21.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.4 million, a 5.4% increase, with the full-year FY2025 number at $21.4 million, up 5.4% from a year prior.
  • Receivables - Other reached $21.4 million in Q4 2025 per PCVX's latest filing, up from $20.3 million in the prior quarter.
  • Over the last five years, Receivables - Other for PCVX hit a ceiling of $21.4 million in Q4 2025 and a floor of $700000.0 in Q2 2021.
  • A 5-year average of $8.8 million and a median of $5.8 million in 2023 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: surged 463.15% in 2024, then grew 5.4% in 2025.
  • Tracing PCVX's Receivables - Other over 5 years: stood at $700000.0 in 2021, then skyrocketed by 306.86% to $2.8 million in 2022, then grew by 26.33% to $3.6 million in 2023, then soared by 463.15% to $20.3 million in 2024, then increased by 5.4% to $21.4 million in 2025.
  • Business Quant data shows Receivables - Other for PCVX at $21.4 million in Q4 2025, $20.3 million in Q4 2024, and $17.6 million in Q3 2024.